{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:10:24Z","timestamp":1794456624921,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    T cells are central drivers of inflammation across autoimmune and inflammatory diseases, yet current therapies inadequately target pathogenic T-cell pathways, limiting durable disease control. Here, we identified a novel, targetable transcriptional-metabolic axis that sustains inflammatory T-cell responses, characterized by NFATc1-regulated activation of MTHFD2-dependent one-carbon metabolism. We demonstrate that NFATc1 directly binds the\n                    <jats:italic>MTHFD2<\/jats:italic>\n                    promoter region, driving metabolic reprogramming in activated T cells from rheumatoid arthritis (RA) patients as well as in experimental arthritis models. Pharmacological inhibition of MTHFD1\/2 using the novel small molecule TH9619 suppresses proinflammatory cytokine production, expands Foxp3\u207a regulatory T cells and protects against cartilage and bone damage in vivo. Proteomic profiling reveals that TH9619 elicits a distinct molecular response in patients\u2019 T cells, divergent from the currently used anti-folate therapy, particularly in inadequate responders. These findings use RA as the proving ground to establish NFATc1-mediated MTHFD2 activation as a critical regulator of sustained T-cell-driven inflammation and support selective MTHFD1\/2 inhibition as a novel, mechanism-based therapeutic strategy for RA.\n                  <\/jats:p>","DOI":"10.1038\/s41392-026-02752-y","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:50:41Z","timestamp":1781074241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting NFATc1-regulated MTHFD2 one-carbon metabolism to suppress sustained T-cell-mediated inflammation in rheumatoid arthritis"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5284-6655","authenticated-orcid":false,"given":"Theodora","family":"Manolakou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjaykumar","family":"Boddul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Samiotaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail Angelos","family":"Panagias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sentis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarc\u00edlia Aparecida","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Argyriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysis","family":"Nikolopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Sanjiv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2597-7809","authenticated-orcid":false,"given":"Karine","family":"Chemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Wermeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Henriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Slipicevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7665-9715","authenticated-orcid":false,"given":"Per-Johan","family":"Jakobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Chatzidionysiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7384-092X","authenticated-orcid":false,"given":"Thomas","family":"Helleday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2752_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388, 2023\u20132038 (2016).","journal-title":"Lancet"},{"key":"2752_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen, J. S. et al. Rheumatoid arthritis. Nat. Rev. Dis. Primers 4, 18001 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2752_CR3","doi-asserted-by":"publisher","first-page":"108680","DOI":"10.1016\/j.clim.2021.108680","volume":"225","author":"T Koga","year":"2021","unstructured":"Koga, T., Kawakami, A. & Tsokos, G. C. Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis. Clin. Immunol. 225, 108680 (2021).","journal-title":"Clin. Immunol."},{"key":"2752_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/ncprheum0142","volume":"2","author":"CM Weyand","year":"2006","unstructured":"Weyand, C. M. & Goronzy, J. J. T-cell-targeted therapies in rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2, 201\u2013210 (2006).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"2752_CR5","doi-asserted-by":"crossref","unstructured":"Chemin, K., Gerstner, C. & Malmstr\u00f6m, V. Effector functions of CD4+ T cells at the site of local autoimmune inflammation-lessons from rheumatoid arthritis. Front. Immunol. 10, 353 (2019).","DOI":"10.3389\/fimmu.2019.00353"},{"key":"2752_CR6","doi-asserted-by":"crossref","unstructured":"Mulhearn, B. et al. Automated clustering reveals CD4+ T cell subset imbalances in rheumatoid arthritis. Front. Immunol. 14, 1094872 (2023).","DOI":"10.3389\/fimmu.2023.1094872"},{"key":"2752_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31519-6","volume":"13","author":"A Argyriou","year":"2022","unstructured":"Argyriou, A. et al. Single cell sequencing identifies clonally expanded synovial CD4+ TPH cells expressing GPR56 in rheumatoid arthritis. Nat. Commun. 13, 4046 (2022).","journal-title":"Nat. Commun."},{"key":"2752_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature20810","volume":"542","author":"DA Rao","year":"2017","unstructured":"Rao, D. A. et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature 542, 110\u2013114 (2017).","journal-title":"Nature"},{"key":"2752_CR9","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1002\/art.38173","volume":"65","author":"S Kobayashi","year":"2013","unstructured":"Kobayashi, S. et al. A distinct human CD4+ T cell subset that secretes CXCL13 in rheumatoid synovium. Arthritis Rheum. 65, 3063\u20133072 (2013).","journal-title":"Arthritis Rheum."},{"key":"2752_CR10","doi-asserted-by":"crossref","unstructured":"Cooles, F. A. H., Isaacs, J. D. & Anderson, A. E. Treg cells in rheumatoid arthritis: an update. Curr. Rheumatol. Rep. 15, 352 (2013).","DOI":"10.1007\/s11926-013-0352-0"},{"key":"2752_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2016.08.009","volume":"25","author":"GS Ducker","year":"2017","unstructured":"Ducker, G. S. & Rabinowitz, J. D. One-carbon metabolism in health and disease. Cell Metab. 25, 27\u201342 (2017).","journal-title":"Cell Metab."},{"key":"2752_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.tem.2024.05.010","volume":"35","author":"Y Qiu","year":"2024","unstructured":"Qiu, Y., Xie, E., Xu, H., Cheng, H. & Li, G. One-carbon metabolism shapes T cell immunity in cancer. Trends Endocrinol. Metab. 35, 967\u2013980 (2024).","journal-title":"Trends Endocrinol. Metab."},{"key":"2752_CR13","doi-asserted-by":"publisher","first-page":"13347","DOI":"10.1073\/pnas.1804149115","volume":"115","author":"N Ron-Harel","year":"2018","unstructured":"Ron-Harel, N. et al. Defective respiration and one-carbon metabolism contribute to impaired na\u00efve T cell activation in aged mice. Proc. Natl. Acad. Sci. USA 115, 13347\u201313352 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2752_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cmet.2016.06.007","volume":"24","author":"N Ron-Harel","year":"2016","unstructured":"Ron-Harel, N. et al. Mitochondrial biogenesis and proteome remodeling promote one-carbon metabolism for T cell activation. Cell Metab. 24, 104\u2013117 (2016).","journal-title":"Cell Metab."},{"key":"2752_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.immuni.2021.10.011","volume":"55","author":"A Sugiura","year":"2022","unstructured":"Sugiura, A. et al. MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function. Immunity 55, 65\u201381.e9 (2022).","journal-title":"Immunity"},{"key":"2752_CR16","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/carcin\/17.8.1695","volume":"17","author":"KL Schalinske","year":"1996","unstructured":"Schalinske, K. L. & Steele, R. D. Methotrexate alters carbon flow through the hepatic folate-dependent one-carbon pool in rats. Carcinogenesis 17, 1695\u20131700 (1996).","journal-title":"Carcinogenesis"},{"key":"2752_CR17","doi-asserted-by":"crossref","unstructured":"Lang, M. B. et al. The actions of methotrexate on endothelial cells are dependent on the shear stress-induced regulation of one carbon metabolism. Front. Immunol. 14, 1209490 (2023).","DOI":"10.3389\/fimmu.2023.1209490"},{"key":"2752_CR18","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1073\/pnas.1820161116","volume":"116","author":"LV Albrecht","year":"2019","unstructured":"Albrecht, L. V., Bui, M. H. & De Robertis, E. M. Canonical Wnt is inhibited by targeting one-carbon metabolism through methotrexate or methionine deprivation. Proc. Natl. Acad. Sci. USA 116, 2987\u20132995 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2752_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.chom.2020.12.008","volume":"29","author":"RR Nayak","year":"2021","unstructured":"Nayak, R. R. et al. Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation. Cell Host Microbe 29, 362\u2013377.e11 (2021).","journal-title":"Cell Host Microbe"},{"key":"2752_CR20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s12015-016-9645-9","volume":"12","author":"OS Beane","year":"2016","unstructured":"Beane, O. S., Darling, L. E. O., Fonseca, V. C. & Darling, E. M. Disparate response to methotrexate in stem versus non-stem cells. Stem Cell Rev. Rep. 12, 340\u2013351 (2016).","journal-title":"Stem Cell Rev. Rep."},{"key":"2752_CR21","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","volume":"73","author":"MH Schiff","year":"2014","unstructured":"Schiff, M. H., Jaffe, J. S. & Freundlich, B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses \u226515 mg may be overcome with subcutaneous administration. Ann. Rheum. Dis. 73, 1549\u20131551 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"2752_CR22","doi-asserted-by":"crossref","unstructured":"Klein-Hessling, S. et al. NFATc1 controls the cytotoxicity of CD8+ T cells. Nat. Commun. 8, 511 (2017).","DOI":"10.1038\/s41467-017-00612-6"},{"key":"2752_CR23","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.3389\/fimmu.2018.02747","volume":"9","author":"JU Lee","year":"2018","unstructured":"Lee, J. U., Kim, L. K. & Choi, J. M. Revisiting the concept of targeting NFAT to control T cell immunity and autoimmune diseases. Front. Immunol. 9, 2747 (2018).","journal-title":"Front. Immunol."},{"key":"2752_CR24","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S1074-7613(02)00329-1","volume":"16","author":"S Chuvpilo","year":"2002","unstructured":"Chuvpilo, S. et al. Autoregulation of NFATc1\/A expression facilitates effector T cells to escape from rapid apoptosis. Immunity 16, 881\u2013895 (2002).","journal-title":"Immunity"},{"key":"2752_CR25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s43018-022-00331-y","volume":"3","author":"N Bonagas","year":"2022","unstructured":"Bonagas, N. et al. Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress. Nat. Cancer 3, 156\u2013172 (2022).","journal-title":"Nat. Cancer"},{"key":"2752_CR26","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s42255-023-00771-5","volume":"5","author":"AC Green","year":"2023","unstructured":"Green, A. C. et al. Formate overflow drives toxic folate trapping in MTHFD1 inhibited cancer cells. Nat. Metab. 5, 642\u2013659 (2023).","journal-title":"Nat. Metab."},{"key":"2752_CR27","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","volume":"403","author":"AP Cope","year":"2024","unstructured":"Cope, A. P. et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet 403, 838\u2013849 (2024).","journal-title":"Lancet"},{"key":"2752_CR28","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","volume":"403","author":"J Rech","year":"2024","unstructured":"Rech, J. et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet 403, 850\u2013859 (2024).","journal-title":"Lancet"},{"key":"2752_CR29","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1056\/NEJMoa035075","volume":"349","author":"JM Kremer","year":"2003","unstructured":"Kremer, J. M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907\u20131915 (2003).","journal-title":"N. Engl. J. Med."},{"key":"2752_CR30","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1073\/pnas.79.11.3632","volume":"79","author":"L Klareskog","year":"1982","unstructured":"Klareskog, L., Forsumt, U., Scheyniust, A., Kabelitz, D. & Wigzell, H. Medical Sciences Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis (HLA-DR antigens\/synovial cells\/collagen type II). Proc. Nati Acad. Sci. USA 79, 3632\u20133636 (1982).","journal-title":"Proc. Nati Acad. Sci. USA"},{"key":"2752_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05044-4","volume":"9","author":"S Tasaki","year":"2018","unstructured":"Tasaki, S. et al. Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. Nat. Commun. 9, 2755 (2018).","journal-title":"Nat. Commun."},{"key":"2752_CR32","doi-asserted-by":"crossref","unstructured":"Brunner, H. I. et al. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Res. Ther. 26, 125 (2024).","DOI":"10.1186\/s13075-024-03347-0"},{"key":"2752_CR33","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2353\/ajpath.2010.100195","volume":"177","author":"TP LaBranche","year":"2010","unstructured":"LaBranche, T. P. et al. Characterization of the KRN cell transfer model of rheumatoid arthritis (KRN-CTM), a chronic yet synchronized version of the K\/BxN mouse. Am. J. Pathol. 177, 1388\u20131396 (2010).","journal-title":"Am. J. Pathol."},{"key":"2752_CR34","doi-asserted-by":"crossref","unstructured":"Gustafsson Sheppard, N. et al. The folate-coupled enzyme MTHFD2 is a nuclear protein and promotes cell proliferation. Sci. Rep. 5, 15029 (2015).","DOI":"10.1038\/srep15029"},{"key":"2752_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1136\/ard.2004.026120","volume":"64","author":"F Lange","year":"2005","unstructured":"Lange, F. et al. Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis. Ann. Rheum. Dis. 64, 599\u2013605 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"2752_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s10020-024-00788-w","volume":"30","author":"H Zheng","year":"2024","unstructured":"Zheng, H. et al. Recent advances of NFATc1 in rheumatoid arthritis-related bone destruction: mechanisms and potential therapeutic targets. Mol. Med. 30, 20 (2024).","journal-title":"Mol. Med."},{"key":"2752_CR37","doi-asserted-by":"crossref","unstructured":"Xiao, Y. et al. Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity. J. Exp. Med. 218, e20181853 (2021).","DOI":"10.1084\/jem.20181853"},{"key":"2752_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.97","volume":"7","author":"GP Mognol","year":"2016","unstructured":"Mognol, G. P., Carneiro, F. R. G., Robbs, B. K., Faget, D. V. & Viola, J. P. B. Cell cycle and apoptosis regulation by NFAT transcription factors: New roles for an old player. Cell Death Dis. 7, e2199 (2016).","journal-title":"Cell Death Dis."},{"key":"2752_CR39","doi-asserted-by":"crossref","unstructured":"Li, Y. et al. MTHFD2 promotes osteoclastogenesis and bone loss in rheumatoid arthritis by enhancing CKMT1-mediated oxidative phosphorylation. BMC Med. 23, 124 (2025).","DOI":"10.1186\/s12916-025-03945-y"},{"key":"2752_CR40","doi-asserted-by":"crossref","unstructured":"Cacciapaglia, F. et al. Modulation of IL-6 receptor\/STAT3 downstream signaling in rheumatoid arthritis patients. Exp. Mol. Pathol. 141, 104951 (2025).","DOI":"10.1016\/j.yexmp.2024.104951"},{"key":"2752_CR41","doi-asserted-by":"publisher","first-page":"10204","DOI":"10.1021\/acs.jmedchem.9b01113","volume":"62","author":"J Kawai","year":"2019","unstructured":"Kawai, J. et al. Discovery of a potent, selective, and orally available MTHFD2 inhibitor (DS18561882) with in vivo antitumor activity. Med. Chem. 62, 10204\u201310220 (2019).","journal-title":"Med. Chem."},{"key":"2752_CR42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"GJ Martinez","year":"2015","unstructured":"Martinez, G. J. et al. The transcription factor NFAT promotes exhaustion of activated CD8+ T cells. Immunity 42, 265\u2013278 (2015).","journal-title":"Immunity"},{"key":"2752_CR43","doi-asserted-by":"crossref","unstructured":"Serfling, E. et al. NFATc1\/A: the other face of NFAT factors in lymphocytes. Cell Commun. Signal. 10, 16 (2012).","DOI":"10.1186\/1478-811X-10-16"},{"key":"2752_CR44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","volume":"6","author":"K Shah","year":"2021","unstructured":"Shah, K., Al-Haidari, A., Sun, J. & Kazi, J. U. T cell receptor (TCR) signaling in health and disease. Signal Transduct. Target. Ther. 6, 412 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2752_CR45","doi-asserted-by":"publisher","first-page":"11381","DOI":"10.1073\/pnas.1019711108","volume":"108","author":"S Sharma","year":"2011","unstructured":"Sharma, S. et al. Dephosphorylation of the nuclear factor of activated T cells (NFAT) transcription factor is regulated by an RNA-protein scaffold complex. Proc. Natl Acad. Sci. USA 108, 11381\u201311386 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2752_CR46","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1182\/blood-2009-12-257378","volume":"116","author":"LV Pham","year":"2010","unstructured":"Pham, L. V., Tamayo, A. T., Li, C., Bueso-Ramos, C. & Ford, R. J. An epigenetic chromatin remodeling role for NFATc1 in transcriptional regulation of growth and survival genes in diffuse large B-cell lymphomas. Blood 116, 3899\u20133906 (2010).","journal-title":"Blood"},{"key":"2752_CR47","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0092-8674(00)81989-3","volume":"87","author":"V Kouskoff","year":"1996","unstructured":"Kouskoff, V. et al. Organ-specific disease provoked by systemic autoimmunity. Cell 87, 811\u2013822 (1996).","journal-title":"Cell"},{"key":"2752_CR48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/978-1-59745-402-5_20","volume":"136","author":"P Monach","year":"2007","unstructured":"Monach, P. et al. The K\/BxN mouse model of inflammatory arthritis: theory and practice. Methods Mol. Med. 136, 269\u2013282 (2007).","journal-title":"Methods Mol. Med."},{"key":"2752_CR49","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"2752_CR50","doi-asserted-by":"publisher","unstructured":"Wickham, H. Ggplot2. ggplot2 (Springer New York, 2009). https:\/\/doi.org\/10.1007\/978-0-387-98141-3.","DOI":"10.1007\/978-0-387-98141-3"},{"key":"2752_CR51","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"2752_CR52","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495\u2013502 (2015).","journal-title":"Nat. Biotechnol."},{"key":"2752_CR53","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41596-018-0082-x","volume":"14","author":"CS Hughes","year":"2019","unstructured":"Hughes, C. S. et al. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat. Protoc. 14, 68\u201385 (2019).","journal-title":"Nat. Protoc."},{"key":"2752_CR54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","volume":"17","author":"V Demichev","year":"2020","unstructured":"Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. D. I. A.-N. N. Neural networks and interference correction enable deep proteome coverage in high throughput Europe PMC Funders Group. Nat. Methods 17, 41\u201344 (2020).","journal-title":"Nat. Methods"},{"key":"2752_CR55","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731\u2013740 (2016).","journal-title":"Nat. Methods"},{"key":"2752_CR56","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607\u2013D613 (2019).","journal-title":"Nucleic Acids Res."},{"key":"2752_CR57","doi-asserted-by":"crossref","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).","DOI":"10.1038\/s41467-019-09234-6"},{"key":"2752_CR58","doi-asserted-by":"publisher","first-page":"W208","DOI":"10.1093\/nar\/gkaa252","volume":"48","author":"C Leporcq","year":"2021","unstructured":"Leporcq, C. et al. TFmotifView: a webserver for the visualization of transcription factor motifs in genomic regions. Nucleic Acids Res. 48, W208\u2013W217 (2021).","journal-title":"Nucleic Acids Res."},{"key":"2752_CR59","doi-asserted-by":"publisher","first-page":"D104","DOI":"10.1093\/nar\/gkaa1057","volume":"49","author":"S Kolmykov","year":"2021","unstructured":"Kolmykov, S. et al. GTRD: an integrated view of transcription regulation. Nucleic Acids Res. 49, D104\u2013D111 (2021).","journal-title":"Nucleic Acids Res."},{"key":"2752_CR60","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/nar\/30.1.322","volume":"30","author":"V Praz","year":"2002","unstructured":"Praz, V., P\u00e9rier, R., Bonnard, C. & Bucher, P. The Eukaryotic promoter database, EPD: new entry types and links to gene expression data. Nucleic Acids Res. 30, 322\u2013324 (2002).","journal-title":"Nucleic Acids Res."},{"key":"2752_CR61","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202001064","volume":"219","author":"SJ Lord","year":"2020","unstructured":"Lord, S. J., Velle, K. B., Dyche Mullins, R. & Fritz-Laylin, L. K. SuperPlots: communicating reproducibility and variability in cell biology. J. Cell Biol. 219, e202001064 (2020).","journal-title":"J. Cell Biol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02752-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02752-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02752-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:05:15Z","timestamp":1781078715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02752-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2752"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02752-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MTHFD1\/2 inhibitors are being developed for clinical use by the company One-Carbon Therapeutics AB. A.S. is an employee of One-Carbon Therapeutics AB. T.H. owns shares in One-Carbon Therapeutics AB, and M.H., A.S., and K.S. have rights in One-Carbon Therapeutics AB. A patent for the use of MTHFD1\/2 inhibitors in RA has been filed by the Helleday Foundation, with T.M., M.H. and T.H. listed as inventors. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}